Pubblicazioni

Autori:

Ostuzzi, Giovanni; Papola, Davide; Gastaldon, Chiara; Schoretsanitis, Georgios; Bertolini, Federico; Amaddeo, Francesco; Cuomo, Alessandro; Emsley, Robin; Fagiolini, Andrea; Imperadore, Giuseppe; Kishimoto, Taishiro; Michencigh, Giulia; Nosé, Michela; Purgato, Marianna; Dursun, Serdar; Stubbs, Brendon; Taylor, David; Thornicroft, Graham; Ward, Philip B; Hiemke, Christoph; Correll, Christoph U; Barbui, Corrado

Titolo:

Safety of psychotropic medications in people with COVID-19: evidence review and practical recommendations

Anno:

2020

Tipologia prodotto:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Lingua:

Inglese

Formato:

Elettronico

Referee:

Sì

Nome rivista:

BMC MEDICINE

ISSN Rivista:

1741-7015

N° Volume:

18

Numero o Fascicolo:

215

Intervallo pagine:

1-14

Parole chiave:

COVID-19; drug–drug interactions; novel coronavirus; psychiatric comorbidity; psychopharmacology

Breve descrizione dei contenuti:

Background: The novel coronavirus pandemic calls for a rapid adaptation of conventional medical practices to meet the evolving needs of such vulnerable patients. People with coronavirus disease (COVID-19) may frequently require treatment with psychotropic medications, but are at the same time at higher risk for safety issues because of the complex underlying medical condition and the potential interaction with medical treatments. Methods: In order to produce evidence-based practical recommendations on the optimal management of psychotropic medications in people with COVID-19, an international, multi-disciplinary working group was established. The methodology of the WHO Rapid Advice Guidelines in the context of a public health emergency and the principles of the AGREE statement were followed. Available evidence informing on the risk of respiratory, cardiovascular, infective, hemostatic, and consciousness alterations related to the use of psychotropic medications, and drug-drug interactions between psychotropic and medical treatments used in people with COVID-19, was reviewed and discussed by the working group. Results: All classes of psychotropic medications showed potentially relevant safety risks for people with COVID-19. A set of practical recommendations was drawn in order to inform frontline clinicians on the assessment of the anticipated risk of psychotropic-related unfavorable events, and the possible actions to take in order to effectively manage this risk, such as when it is appropriate to avoid, withdraw, switch, or adjust the dose of the medication. Conclusions: The present evidence-based recommendations will improve the quality of psychiatric care in people with COVID-19, allowing an appropriate management of the medical condition without worsening the psychiatric condition and vice versa.

Pagina Web:

https://doi.org/10.1186/s12916-020-01685-9
http://www.ncbi.nlm.nih.gov/pmc/articles/pmc7360478/

Id prodotto:

115514

Handle IRIS:

11562/1021776

ultima modifica:

17 novembre 2022

Citazione bibliografica:

Ostuzzi, Giovanni; Papola, Davide; Gastaldon, Chiara; Schoretsanitis, Georgios; Bertolini, Federico; Amaddeo, Francesco; Cuomo, Alessandro; Emsley, Robin; Fagiolini, Andrea; Imperadore, Giuseppe; Kishimoto, Taishiro; Michencigh, Giulia; Nosé, Michela; Purgato, Marianna; Dursun, Serdar; Stubbs, Brendon; Taylor, David; Thornicroft, Graham; Ward, Philip B; Hiemke, Christoph; Correll, Christoph U; Barbui, Corrado, Safety of psychotropic medications in people with COVID-19: evidence review and practical recommendations «BMC MEDICINE» , vol. 18 , n. 215 , 2020 , pp. 1-14

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo